Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG Trial E4402 (RESORT)

Lynne I. Wagner, Fengmin Zhao, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, John C. Krauss, Ranjana H. Advani, Ronald S. Go, Thomas Matthew Habermann, Joseph W. Leach, Brian O'Connor, Stephen J. Schuster, David Cella, Sandra J. Horning, Brad S. Kahl

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to compare illness-related anxiety among participants in the Rituximab Extended Schedule or Retreatment Trial (RESORT) randomly assigned to maintenance rituximab (MR) versus rituximab re-treatment (RR). A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style. Patients and Methods: Patients (N = 253) completed patient-reported outcome (PRO) measures at random assignment to MR or RR (baseline); at 3, 6, 12, 24, 36, and 48 months after random assignment; and at rituximab failure. PRO measures assessed illness-related anxiety and coping style, and secondary end points including general anxiety, worry and interference with emotional well-being, depression, and health-related quality of life (HRQoL). Patients were classified as using an active or avoidant illness-related coping style. Independent sample t tests and linear mixed-effects models were used to identify treatment arm differences on PRO end points and differences based on coping style. Results: Illness-related anxiety was comparable between treatment arms at all time points ( P > .05), regardless of coping style (active or avoidant). Illness-related anxiety and general anxiety significantly decreased over time on both arms. HRQoL scores were relatively stable and did not change significantly from baseline for both arms. An avoidant coping style was associated with significantly higher anxiety (18% and 13% exceeded clinical cutoff points at baseline and 6 months, respectively) and poorer HRQoL compared with an active coping style ( P < .001), regardless of treatment arm assignment. Conclusion: Surveillance until RR at progression was not associated with increased anxiety compared with MR, regardless of coping style. Avoidant coping was associated with higher anxiety and poorer HRQoL.

Original languageEnglish (US)
Pages (from-to)740-748
Number of pages9
JournalJournal of Clinical Oncology
Volume33
Issue number7
DOIs
StatePublished - Mar 1 2015

Fingerprint

Retreatment
Tumor Burden
Non-Hodgkin's Lymphoma
Appointments and Schedules
Anxiety
Quality of Life
Maintenance
Therapeutics
Rituximab
Depression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens : Results from ECOG Trial E4402 (RESORT). / Wagner, Lynne I.; Zhao, Fengmin; Hong, Fangxin; Williams, Michael E.; Gascoyne, Randy D.; Krauss, John C.; Advani, Ranjana H.; Go, Ronald S.; Habermann, Thomas Matthew; Leach, Joseph W.; O'Connor, Brian; Schuster, Stephen J.; Cella, David; Horning, Sandra J.; Kahl, Brad S.

In: Journal of Clinical Oncology, Vol. 33, No. 7, 01.03.2015, p. 740-748.

Research output: Contribution to journalArticle

Wagner, LI, Zhao, F, Hong, F, Williams, ME, Gascoyne, RD, Krauss, JC, Advani, RH, Go, RS, Habermann, TM, Leach, JW, O'Connor, B, Schuster, SJ, Cella, D, Horning, SJ & Kahl, BS 2015, 'Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG Trial E4402 (RESORT)', Journal of Clinical Oncology, vol. 33, no. 7, pp. 740-748. https://doi.org/10.1200/JCO.2014.57.6801
Wagner, Lynne I. ; Zhao, Fengmin ; Hong, Fangxin ; Williams, Michael E. ; Gascoyne, Randy D. ; Krauss, John C. ; Advani, Ranjana H. ; Go, Ronald S. ; Habermann, Thomas Matthew ; Leach, Joseph W. ; O'Connor, Brian ; Schuster, Stephen J. ; Cella, David ; Horning, Sandra J. ; Kahl, Brad S. / Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens : Results from ECOG Trial E4402 (RESORT). In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 7. pp. 740-748.
@article{3aa09484dc5f4b27b03bebe66eea62fd,
title = "Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG Trial E4402 (RESORT)",
abstract = "Purpose: The purpose of this study was to compare illness-related anxiety among participants in the Rituximab Extended Schedule or Retreatment Trial (RESORT) randomly assigned to maintenance rituximab (MR) versus rituximab re-treatment (RR). A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style. Patients and Methods: Patients (N = 253) completed patient-reported outcome (PRO) measures at random assignment to MR or RR (baseline); at 3, 6, 12, 24, 36, and 48 months after random assignment; and at rituximab failure. PRO measures assessed illness-related anxiety and coping style, and secondary end points including general anxiety, worry and interference with emotional well-being, depression, and health-related quality of life (HRQoL). Patients were classified as using an active or avoidant illness-related coping style. Independent sample t tests and linear mixed-effects models were used to identify treatment arm differences on PRO end points and differences based on coping style. Results: Illness-related anxiety was comparable between treatment arms at all time points ( P > .05), regardless of coping style (active or avoidant). Illness-related anxiety and general anxiety significantly decreased over time on both arms. HRQoL scores were relatively stable and did not change significantly from baseline for both arms. An avoidant coping style was associated with significantly higher anxiety (18{\%} and 13{\%} exceeded clinical cutoff points at baseline and 6 months, respectively) and poorer HRQoL compared with an active coping style ( P < .001), regardless of treatment arm assignment. Conclusion: Surveillance until RR at progression was not associated with increased anxiety compared with MR, regardless of coping style. Avoidant coping was associated with higher anxiety and poorer HRQoL.",
author = "Wagner, {Lynne I.} and Fengmin Zhao and Fangxin Hong and Williams, {Michael E.} and Gascoyne, {Randy D.} and Krauss, {John C.} and Advani, {Ranjana H.} and Go, {Ronald S.} and Habermann, {Thomas Matthew} and Leach, {Joseph W.} and Brian O'Connor and Schuster, {Stephen J.} and David Cella and Horning, {Sandra J.} and Kahl, {Brad S.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1200/JCO.2014.57.6801",
language = "English (US)",
volume = "33",
pages = "740--748",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens

T2 - Results from ECOG Trial E4402 (RESORT)

AU - Wagner, Lynne I.

AU - Zhao, Fengmin

AU - Hong, Fangxin

AU - Williams, Michael E.

AU - Gascoyne, Randy D.

AU - Krauss, John C.

AU - Advani, Ranjana H.

AU - Go, Ronald S.

AU - Habermann, Thomas Matthew

AU - Leach, Joseph W.

AU - O'Connor, Brian

AU - Schuster, Stephen J.

AU - Cella, David

AU - Horning, Sandra J.

AU - Kahl, Brad S.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose: The purpose of this study was to compare illness-related anxiety among participants in the Rituximab Extended Schedule or Retreatment Trial (RESORT) randomly assigned to maintenance rituximab (MR) versus rituximab re-treatment (RR). A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style. Patients and Methods: Patients (N = 253) completed patient-reported outcome (PRO) measures at random assignment to MR or RR (baseline); at 3, 6, 12, 24, 36, and 48 months after random assignment; and at rituximab failure. PRO measures assessed illness-related anxiety and coping style, and secondary end points including general anxiety, worry and interference with emotional well-being, depression, and health-related quality of life (HRQoL). Patients were classified as using an active or avoidant illness-related coping style. Independent sample t tests and linear mixed-effects models were used to identify treatment arm differences on PRO end points and differences based on coping style. Results: Illness-related anxiety was comparable between treatment arms at all time points ( P > .05), regardless of coping style (active or avoidant). Illness-related anxiety and general anxiety significantly decreased over time on both arms. HRQoL scores were relatively stable and did not change significantly from baseline for both arms. An avoidant coping style was associated with significantly higher anxiety (18% and 13% exceeded clinical cutoff points at baseline and 6 months, respectively) and poorer HRQoL compared with an active coping style ( P < .001), regardless of treatment arm assignment. Conclusion: Surveillance until RR at progression was not associated with increased anxiety compared with MR, regardless of coping style. Avoidant coping was associated with higher anxiety and poorer HRQoL.

AB - Purpose: The purpose of this study was to compare illness-related anxiety among participants in the Rituximab Extended Schedule or Retreatment Trial (RESORT) randomly assigned to maintenance rituximab (MR) versus rituximab re-treatment (RR). A secondary objective was to examine whether the superiority of MR versus RR on anxiety depended on illness-related coping style. Patients and Methods: Patients (N = 253) completed patient-reported outcome (PRO) measures at random assignment to MR or RR (baseline); at 3, 6, 12, 24, 36, and 48 months after random assignment; and at rituximab failure. PRO measures assessed illness-related anxiety and coping style, and secondary end points including general anxiety, worry and interference with emotional well-being, depression, and health-related quality of life (HRQoL). Patients were classified as using an active or avoidant illness-related coping style. Independent sample t tests and linear mixed-effects models were used to identify treatment arm differences on PRO end points and differences based on coping style. Results: Illness-related anxiety was comparable between treatment arms at all time points ( P > .05), regardless of coping style (active or avoidant). Illness-related anxiety and general anxiety significantly decreased over time on both arms. HRQoL scores were relatively stable and did not change significantly from baseline for both arms. An avoidant coping style was associated with significantly higher anxiety (18% and 13% exceeded clinical cutoff points at baseline and 6 months, respectively) and poorer HRQoL compared with an active coping style ( P < .001), regardless of treatment arm assignment. Conclusion: Surveillance until RR at progression was not associated with increased anxiety compared with MR, regardless of coping style. Avoidant coping was associated with higher anxiety and poorer HRQoL.

UR - http://www.scopus.com/inward/record.url?scp=84925238573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925238573&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.57.6801

DO - 10.1200/JCO.2014.57.6801

M3 - Article

C2 - 25605841

AN - SCOPUS:84925238573

VL - 33

SP - 740

EP - 748

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -